Amy Pooler
About Amy Pooler
Amy Pooler Head of Research
Amy Pooler serves as the Head of Research, spearheading various projects and initiatives in the field. Her role involves leading research efforts, overseeing projects, and guiding teams towards achieving their objectives. Amy Pooler's leadership in research directly contributes to advancements in addressing complex neurological and genetic conditions.
Amy Pooler Ph.D. Expertise
Amy Pooler holds a Ph.D., showcasing her advanced knowledge and expertise in her field. Her academic background has equipped her with the skills necessary to lead cutting-edge research projects. Amy Pooler’s specialization includes the use of engineered zinc finger protein transcription factors, a critical area of study for developing treatments for neurological and genetic disorders.
Persistent Repression of Tau Research by Amy Pooler
Amy Pooler has published significant research on the persistent repression of tau in the brain using engineered zinc finger protein transcription factors. Her work in this area addresses tauopathies, which are associated with various neurodegenerative diseases. Amy Pooler’s research provides valuable insights into potential therapeutic approaches for these conditions.
Amy Pooler's Contributions to Gene and Cell Therapy
Amy Pooler presented preclinical data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. Her contributions in this space highlight her role in advancing gene and cell therapy research. Amy Pooler's work focuses on developing innovative treatments for chronic neuropathic pain by targeting the SCN9A gene and other genetic targets.
Amy Pooler's Research on Prion Disease and Tauopathies
Amy Pooler has worked on preclinical data for prion disease, demonstrating significant repression of prion protein in neurons. Additionally, she has published preclinical data in Science Advances on tau-targeted zinc finger repressors for tauopathies. These efforts are crucial in understanding and potentially treating devastating neurological conditions.
Amy Pooler's Role in ALS and Huntington's Disease Research
Amy Pooler has collaborated on research targeting the C9ORF72 gene associated with amyotrophic lateral sclerosis (ALS), and she has worked on preclinical genome engineering product candidates for Huntington's Disease in partnership with Takeda. Amy Pooler's involvement in these projects underscores her commitment to advancing therapeutic options for these serious genetic disorders.
Preclinical Data Presentation at AD/PD by Amy Pooler
Amy Pooler presented preclinical data at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD). Her work presented at this conference showcases her contributions to understanding and addressing neurodegenerative diseases. Amy Pooler's research aims to pave the way for new treatments and improve patient outcomes in the field of neurology.